PropertyValue
?:abstract
  • BACKGROUND AND AIMS: Diabetes is one of the most common comorbidities, and it is unequivocally associated with poorer outcomes regarding coronavirus disease of 2019 (COVID-19). Preliminary findings showed that mortality was lowered in those who consume metformin vs who did not, and given its low cost and widespread availability; thus, metformin is an attractive and potential regimen for mitigating excessive risk in diabetic populations. METHODS: Several medical databases (Pubmed, EuropePMC, EBSCOhost, Proquest, Cochrane library) and two health-science preprint servers (preprint.org and Medrxiv) were systematically searched for relevant literature. RESULTS: Nine studies with 10,233 subjects were included in the qualitative and quantitative synthesis. Meta-analysis showed that metformin is associated with lower mortality in pooled non-adjusted model (OR 0.45 [0.25, 0.81], p = 0.008; I2: 63.9%, p = 0.026) and pooled adjusted model (OR 0.64 [0.43, 0.97], p = 0.035; I2: 52.1%, p = 0.064). CONCLUSION: The analysis showed that metformin consumption was associated with lower mortality. A randomized controlled trial is needed to confirm this finding.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.dsx.2020.11.006
?:doi
?:journal
  • Diabetes_Metab_Syndr
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/fb570d99c0d2b879424ba6d23cc92c41b1c7b6d4.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7657016.xml.json
?:pmcid
?:pmid
?:pmid
  • 33395778.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis
?:type
?:year
  • 2020-11-11

Metadata

Anon_0  
expand all